Praxis Precision Medicines hosted an Investor Day in New York City to detail its commercial strategy and launch plans for ulixacaltamide in essential tremor and relutrigine in DEEs. The company also provided an expanded pipeline update, including plans to initiate studies for ulixacaltamide in Parkinson’s disease and autism spectrum disorder in 2027.
Praxis Precision Medicines reported a net loss of $94.2 million for the third quarter of 2026, compared to $73.9 million in the prior year period, driven by increased general and administrative expenses. The company significantly strengthened its balance sheet through a follow-on public offering, ending September 30, 2026, with $1.31 billion in total assets including $745.3 million in cash and marketable securities.
Praxis Precision Medicines reported third quarter 2026 financial results, highlighting a strong cash position of $1.3 billion to support operations into 2028. The company is preparing for two potential commercial launches with FDA PDUFA dates for relutrigine on December 27, 2026, and ulixacaltamide on January 29, 2027. Management is currently hiring a field sales force and expects topline results from the EMERALD study in the fourth quarter of 2026.
Term
Q3 2026
“We are entering a defining period for Praxis, with two key regulatory milestones ahead and the opportunity to become a commercial CNS company. Our teams are working to bring relutrigine and ulixacaltamide to patients who need new options. The relutrigine team is fully hired, and we expect the ulixacaltamide sales force to be in place this quarter. We continue to advance our broader pipeline, with EMERALD and EMBRAVE3 progressing toward important readouts. We look forward to discussing our commercial strategies, launch readiness and pipeline at our Investor Day later this week.”
Marcio Souza, president and chief executive officer